Logotype for Medexus Pharmaceuticals Inc

Medexus Pharmaceuticals (MDP) Q2 2027 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Medexus Pharmaceuticals Inc

Q2 2027 earnings summary

12 Nov, 2026

Executive summary

  • Q2 FY2027 net revenue was $29.100M, up 17.6% YoY; Adjusted EBITDA was $5.1M, operating income $2.440M and net income $0.813M, versus a $0.315M loss.

  • Q2 revenue, Adjusted EBITDA, operating income and net income were quarterly records since fiscal Q4 2025.

  • GRAFAPEX achieved record quarterly product-level net revenue of $5.7M, with results described as in line with FY2027 expectations.

Financial highlights

  • H1 revenue was $57.685M, up 16.9% YoY; growth reflected GRAFAPEX, IXINITY and Rasuvo, partly offset by prior-year royalty revenue.

  • H1 Adjusted EBITDA increased 25.2% to $9.8M and operating income rose 104.5% to $4.554M, primarily reflecting GRAFAPEX operating leverage.

  • Q2 gross profit was $16.274M versus $13.786M YoY; SG&A was $13.3M, up 11.6%, mainly due to GRAFAPEX commercialization spending.

  • Q2 operating cash flow was $5.4M versus $3.3M YoY; H1 operating cash flow was $4.677M versus $7.256M, reflecting higher income taxes and other factors.

  • H1 net income was $1.357M versus $0.2M; H1 basic and diluted EPS were $0.04 versus $0.01.

Outlook and guidance

  • FY2027 GRAFAPEX product-level net revenue guidance remains $30M–$32M, requiring acceleration in the remainder of the year through expected adoption and repeat orders.

  • Long-term GRAFAPEX annual product-level net revenue target is $100M–$175M within five years of launch; long-term product-level Adjusted Gross Margin is expected to reach ~85%.

  • GRAFAPEX personnel and infrastructure spending is expected at $3M–$4M per quarter through FY2027; additional field-force resources began deployment in Q2.

  • Meaningful FY2027 operating cash flow is expected as GRAFAPEX scales; working capital may affect quarterly cash flow. Cash and expected operating cash flow are expected to cover operating and capital needs for at least 12 months.

  • UM171 Cell Therapy commercialization in Canada is not expected before calendar 2028, or potentially 2031 depending on regulatory pathways.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Medexus Pharmaceuticals